Abivax offers high-upside exposure to a de-risked oral IBD asset, but regulatory execution, launch capability and post-2030 patent protection determine whether the asymmetric €215.16 target is realized.
Overview
Abivax is a clinical-stage biotechnology company whose valuation is primarily tied to obefazimod, a first-in-class oral miR-124 enhancer targeting moderate-to-severe ulcerative colitis and potentially Crohn’s disease. The drug seeks to combine biologic-like efficacy with convenient once-daily dosing and a safety profile free of the JAK-class black-box warnings. **Clinical de-risking is meaningful:** placebo-adjusted remission was 19.3% in ABTECT-1 and 13.4% in ABTECT-2, while 44-week maintenance remission reached 37.2%–51.3%. The commercial opportunity is substantial, with the combined IBD market forecast to exceed $44.0 billion by 2032 and risk-adjusted peak sales estimates of approximately €4.0 billion in UC and €3.5 billion in Crohn’s disease. H1 2026 losses widened as R&D reached €112.4 million and net loss €165.9 million, but the July financing created approximately €1.17 billion of pro-forma liquidity and runway into Q4 2029. At €101.30, the stock carries an €8.03 billion market capitalization and €7.53 billion EV, with no meaningful P/S multiple because it is pre-commercial. The consensus target is €149.00, while the report’s probability-weighted five-year target is €215.16. Near-term catalysts are the late-Q4 2026 NDA, 2027 approval and launch, and mid-2027 Crohn’s data.